GSK583
SIGMA/SML1960 - ≥98% (HPLC)
Synonym: GSK583; 6-
CAS Number: 1346547-00-9
Empirical Formula (Hill Notation): C20H19FN4O2S
Molecular Weight: 398.45
Linear Formula: C20H19FN4O2S
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI key | XLOGLWKOHPIJLV-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | Fc1cc2c([nH]nc2Nc3c4c(ncc |
| solubility | DMSO: 20 mg/mL, clear |
| storage condition | desiccated |
| protect from light | |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | An ATP-competitive RIP2 (RIPK2) inhibitor with in vitro and in vivo efficacy against NOD1- and NOD2-dependent pro-inflammatory cytokines release. |
| Biochem/physiol Actions: | GSK583 is a cell-permeable indazolylquinolinamine that acts as an ATP-competitive (IC50 = 2 & 5 nM using rat & human RIPK2, respectively) inhibitor against RIPK2 kinase activity (66.6% inhibition at 1 μM; [ATP] = 10 μM), exhibiting much reduced or no inhibitory potency against a panel of 209 other kinases <34% inhibition at 1 μM; [ATP] = 10 ?M). GSK583 selectively inhibits against NOD1- and NOD2-, but not TLR2-, TLR4-, TLR7-. IL-1R-, or TNFR-dependent pro-inflammatory cytokines release (>95% inhibition vs. <40% inhibition at 1 ?M using primary human monocytes stimulated with respective ligands). GSK583 effectively inhibits TNF? and IL-6 production from Crohn′s disease (CD) and ulcerative colitis (UC) patients intestinal explant cultures ex vivo (IC50 = 200 nM) and is efficacious against NOD1 ligand FK156- and NOD2 ligand MDP-induced inflammatory responses in mice and rats (10 mg/kg p.o.) in vivo. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |